Clinical Infrastructures to Support Proteomic Studies of Tissue and Fluids in Breast Cancer*

The Danish Breast Cancer Cooperative Group (DBCG) was established in 1977 with the aim to ensure optimal breast cancer diagnostics and therapeutic modalities on a nationwide basis. DBCG was organized in such a way so it represents a broad interdisciplinary collaboration with established clinical databases and biobanks. This review summarizes the infrastructures, such as those of the DBCG, that are required to facilitate translational research studies aiming at further diagnostic and therapeutic improvements through interactions directed at prevention, early diagnosis, and treatment of primary breast cancer.

[1]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[2]  Massimo Gion,et al.  Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. , 2003, International journal of oncology.

[3]  J. Gietema,et al.  Long-term survivors of acute lymphoblastic leukemia. , 2003, The New England journal of medicine.

[4]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Balslev,et al.  674 Topoisomerase II alpha (TOP2A) alterations as a predictive marker for epirubicin sensitivity in 805 high-risk breast cancer patients. A randomised DBCG trial (DBCG89D) , 2003 .

[6]  D. Bentrem,et al.  Oestrogens, Oestrogen Receptors and Breast Cancer , 2003 .

[7]  M. Piccart,et al.  Progress in systemic therapy for breast cancer: an overview and perspectives , 2003 .

[8]  Lars Bolund,et al.  Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research* , 2003, Molecular & Cellular Proteomics.

[9]  Sridhar Ramaswamy,et al.  DNA microarrays in breast cancer: the promise of personalised medicine , 2003, The Lancet.

[10]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Feig.  IARC Handbooks of Cancer Prevention , 2003 .

[12]  Kornelia Polyak,et al.  Molecular markers in ductal carcinoma in situ of the breast. , 2003, Molecular cancer research : MCR.

[13]  N. Brünner,et al.  Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * , 2003, Molecular & Cellular Proteomics.

[14]  P. Boyle,et al.  Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.

[15]  C. Rose,et al.  A Systematic Overview of Radiation Therapy Effects in Breast Cancer , 2003, Acta oncologica.

[16]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[17]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[18]  N. Sneige,et al.  Molecular and Biologic Markers of Premalignant Lesions of Human Breast , 2002, Advances in anatomic pathology.

[19]  N. Brünner,et al.  Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Ingvar Andersson,et al.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.

[21]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[22]  P. Goss,et al.  Aromatase inhibitors in the treatment and prevention of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Brünner,et al.  The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. , 2000, Cancer research.

[24]  L. Tabár,et al.  The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. , 2000, Radiologic clinics of North America.

[25]  L. Fielding,et al.  American Joint Committee on Cancer Prognostic Factors Consensus Conference , 1999, Cancer.

[26]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[27]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[28]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[29]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[30]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[31]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[32]  D C Slawson,et al.  Efficacy of screening mammography. , 1995, The Journal of family practice.

[33]  S. Rubin,et al.  Efficacy of screening mammography. A meta-analysis. , 1995, JAMA.

[34]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[35]  S. Wall,et al.  Breast cancer screening with mammography: overview of Swedish randomised trials , 1993, The Lancet.

[36]  J. Weber,et al.  Closing in on a breast cancer gene on chromosome 17q. , 1992, American journal of human genetics.

[37]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[38]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[39]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[40]  M. Ro̸rth,et al.  Organisation of the Danish adjuvant trials in breast cancer. , 1981, Danish medical bulletin.

[41]  B. Fisher.  Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture. , 1980, Cancer research.

[42]  S J Pocock,et al.  Long-term survival of patients with breast cancer: a study of the curability of the disease. , 1979, British medical journal.

[43]  H. B. Stoner,et al.  Measuring the severity of injury. , 1977, British medical journal.

[44]  F. Schabel.  Concepts for systemic treatment of micrometastases , 1975, Cancer.

[45]  B. Fisher,et al.  The interrelationship of hematogenous and lymphatic tumor cell dissemination. , 1966, Surgery, gynecology & obstetrics.

[46]  G. Moore,et al.  Chemotherapy as an adjuvant to surgery , 1963 .

[47]  R. Fugmann,et al.  A role for chemotherapy as an adjunct to surgery. , 1957, Cancer research.

[48]  W. Halsted.  I. The Results of Radical Operations for the Cure of Carcinoma of the Breast. , 1907, Annals of surgery.

[49]  S. Horning.  Something old, something few, something subjective, something déjà vu. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[51]  J. Mackay.  IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-1) - a randomised prevention trial , 2002 .

[52]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.